We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / PRODUCT PORTFOLIO
OTHER THERAPEUTIC AREAS

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.
Product Indication Dosage form Strength
Methocarbamol Muscle spasms, pain Film-coated tablets 500, 750 and 1500 mg
Noxiall® Useful to contrast chronic and neuropathic pain Jan 2017
Olanzapine Psychosis, schizophrenia Film-coated tablets 2.5, 5, 7.5, 10, 15 and 20 mg
Olanzapine Psychosis, schizophrenia Orodispersable tablets 5, 10, 15 and 20 mg
Partnena® Rational combination for the prophylaxis of migraine, the nociceptive modulation and the reduction of tension states Jan 2014
Pramipexol Parkinson's Tablets 0.088, 0.18, 0.35, 0.7 and 1.1 mg
Pregabaline * Neuropathic pain Tablets 25, 50, 75, 100, 150, 200, 225 and 300 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Film-coated tablets 25, 50, 100, 150, 200, 300 and 400 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Orodispersable tablets 25 and 50 mg
Quetidia® oral solution Useful for the management of anxiety disorders Sep 2017
Rasagiline Parkinson's Tablets 1 mg
Risperidone Psychosis, schizophrenia, bipolar disoder Film-coated tablets 0.5, 1, 2, 3, 4 and 6 mg
Rotigotine Parkinson's Patches 1, 2, 3, 4, 6 and 8 mg/24h
Seripnol® Useful to promote relaxation and sleep Mar 2012
Seripnol® drops Useful to promote relaxation and sleep Apr 2014


Sodium Oxybate Narcolepsy Oral solution 500 mg/ml
Sultiame * Epilepsy, convulsions Film-coated tablets 50, 100 and 200 mg
Tolcapone Parkinson's Film-coated tablets 100 mg
Tranylcypromine Depression Film-coated tablets 10, 20 and 40 mg
Trazodone Depression XR tablets 75 and 150 mg
FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.